SwitzerlandSwitzerland

Avastin slows down advanced ovarian cancer: Phase III study results

26.02.2010

Basel – Roche’s blockbuster drug Avastin (bevacizumab) could add another billion to its $5.75 billion sales in 2009, analysts said after the company announced positive preliminary outcomes of a 3-arm phase III study (NCT00262847) in advanced ovarian cancer. According to Roche, the combination of the anti-angiogenetic monoclonal antibody plus carboplatin and paclitaxel, followed by maintenance use of Avastin, prolonged progression-free survival compared to placebo and Avastin monotherapy. A preliminary safety assessment noted adverse events previously observed in pivotal trials with Avastin. Data from the study will be submitted for presentation at the 2010 American Society of Clinical Oncology (ASCO) annual meeting, June 4 to 8, 2010. Roche included around 2,000 patients with stage III or stage IV ovarian epithelial, primary peritoneal cancer, or fallopian tube cancer in the study. The primary endpoint was comparison of overall survival in patients with these patients in the 3 study arms. Secondary endpoint include comparison of time to progression in patients treated with these regimens. Additionally, incidence of severe toxicity of these regimens was compared as well as quality of life.


SwitzerlandSwitzerland

30.03.2012

Basel/Hinxton (UK) – Two European teams have created huge repositories of cancer genomics data that help predict drug response. Swiss Novartis and the Boston-based Broad Institute have combined data obtained from large-scale...

SwitzerlandSwitzerland

27.03.2012

London/Lausanne – The global private equity firm Celtic Therapeutic L.L.L.P. believes in the power of antibody-drug conjugates (ADCs). It is investing $50m in a new Switzerland-based company called ADC Therapeutics Sarl which...

SwitzerlandSwitzerland

26.03.2012

Basel/Vienna - Following promising results from a Phase III study, Roche has submitted a regulatory application to EMA for subcutaneous Herceptin (trastuzumab) to treat HER2-positive breast cancer. Roche said subcutaneous...

SwitzerlandSwitzerland

09.03.2012

After the US Food & Drug Administration forced Swiss generics giant Sandoz AG to update its production facilities in Quebec, there are now fears that supplies of some medicines could grow tight in Canada. The regulatory authority...

SwitzerlandSwitzerland

08.03.2012

The hepatitis C space has seen a string of large deals in the last weeks that include a US$11bn buyout of Pharmasset by Gilead. Now Novartis is also trying to get in the game with the purchase of a global exclusive licence from...

SwitzerlandSwitzerland

06.03.2012

Allschwil – Swiss Actelion Ltd. has strengthened its commercial offerings by securing rights in certain countries to Auxilium’s biotech drug Xiaflex for treating tissue buildup under the skin. The US pharma is to receive US$10m...

SwitzerlandSwitzerland

06.03.2012

Zug – Life Sciences specialist HBM partners has raised €90m in the first close of its HBM BioCapital II fund, which will invest in revenue-generating companies in the pharmaceuticals, medical device and diagnostics sectors....

SwitzerlandSwitzerland

05.03.2012

Stans – Mondobiotech, a drug discovery company in troubled waters, could soon be under Italian ownership: The Swiss biotech announced it has entered into exclusive negotiations with Milan-based provider of pharmaceutical and...

Displaying results 1 to 10 out of 276

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-switzerland/article/avastin-slows-down-advanced-ovarian-cancer-phase-iii-study-results.html

Events

All Events

Stock list

All quotes

TOP

  • BIOFRONTERA2.44 EUR10.91%
  • WILEX2.19 EUR4.29%
  • PAION3.28 EUR1.86%

FLOP

  • SANTHERA83.00 CHF-4.54%
  • EVOLVA1.19 CHF-4.03%
  • BB BIOTECH149.65 EUR-2.95%

TOP

  • PAION3.28 EUR36.1%
  • CO.DON3.05 EUR24.0%
  • FORMYCON8.17 EUR15.9%

FLOP

  • CYTOS0.18 CHF-28.0%
  • EVOTEC3.05 EUR-18.0%
  • 4SC1.01 EUR-14.4%

TOP

  • SANTHERA83.00 CHF2044.7%
  • PAION3.28 EUR245.3%
  • CO.DON3.05 EUR214.4%

FLOP

  • CYTOS0.18 CHF-95.3%
  • 4SC1.01 EUR-46.0%
  • MOLOGEN6.64 EUR-44.2%

No liability assumed, Date: 01.10.2014


Current issue

All issues

Product of the week

Products